181 related articles for article (PubMed ID: 19401697)
21. Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies.
Pugh TJ; Chen C; Rabinovitch R; Eckhardt SG; Rusthoven KE; Swing R; Raben D
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):521-6. PubMed ID: 20133082
[TBL] [Abstract][Full Text] [Related]
22. Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I study.
Ho C; Sangha R; Beckett L; Tanaka M; Lau DH; Eisen DB; Burich RA; Luciw P; Khan I; Mack PC; Gandara DR; Davies AM
Invest New Drugs; 2011 Aug; 29(4):680-7. PubMed ID: 20148348
[TBL] [Abstract][Full Text] [Related]
23. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR
Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
Lin CC; Calvo E; Papadopoulos KP; Patnaik A; Sarantopoulos J; Mita AC; Preston GG; Mita MM; Rodon J; Mays T; Yeh IT; O'Rourke P; Takimoto CH; Dancey JE; Chen H; Tolcher AW
Cancer Chemother Pharmacol; 2009 May; 63(6):1065-71. PubMed ID: 18795291
[TBL] [Abstract][Full Text] [Related]
25. A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.
Beaven AW; Shea TC; Moore DT; Feldman T; Ivanova A; Ferraro M; Ford P; Smith J; Goy A
Leuk Lymphoma; 2012 Feb; 53(2):254-8. PubMed ID: 21812533
[TBL] [Abstract][Full Text] [Related]
26. Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies.
Guarino MJ; Schneider CJ; Hosford MA; Brahmer JR; Rudin CM; Finckenstein FG; Philip-Norton RE; Lu H; Weber MR; Ettinger DS
Oncologist; 2009 Feb; 14(2):119-24. PubMed ID: 19182243
[TBL] [Abstract][Full Text] [Related]
27. Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Chung CH; Aulino J; Muldowney NJ; Hatakeyama H; Baumann J; Burkey B; Netterville J; Sinard R; Yarbrough WG; Cmelak AJ; Slebos RJ; Shyr Y; Parker J; Gilbert J; Murphy BA
Ann Oncol; 2010 Apr; 21(4):864-870. PubMed ID: 19850643
[TBL] [Abstract][Full Text] [Related]
28. A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer.
O'Neil BH; Raftery L; Calvo BF; Chakravarthy AB; Ivanova A; Myers MO; Kim HJ; Chan E; Wise PE; Caskey LS; Bernard SA; Sanoff HK; Goldberg RM; Tepper JE
Clin Colorectal Cancer; 2010 Apr; 9(2):119-25. PubMed ID: 20378507
[TBL] [Abstract][Full Text] [Related]
29. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
30. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
Davies AM; Ho C; Metzger AS; Beckett LA; Christensen S; Tanaka M; Lara PN; Lau DH; Gandara DR
J Thorac Oncol; 2007 Dec; 2(12):1112-6. PubMed ID: 18090584
[TBL] [Abstract][Full Text] [Related]
31. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.
Janjigian YY; Azzoli CG; Krug LM; Pereira LK; Rizvi NA; Pietanza MC; Kris MG; Ginsberg MS; Pao W; Miller VA; Riely GJ
Clin Cancer Res; 2011 Apr; 17(8):2521-7. PubMed ID: 21248303
[TBL] [Abstract][Full Text] [Related]
32. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
Kang MJ; Hong YS; Kim KP; Kim SY; Baek JY; Ryu MH; Lee JL; Chang HM; Kim MJ; Chang HJ; Kang YK; Kim TW
Invest New Drugs; 2012 Aug; 30(4):1607-13. PubMed ID: 21706149
[TBL] [Abstract][Full Text] [Related]
33. Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.
Cohen SJ; Engstrom PF; Lewis NL; Langer CJ; McLaughlin S; Beard M; Weiner LM; Meropol NJ
Am J Clin Oncol; 2008 Feb; 31(1):1-5. PubMed ID: 18376220
[TBL] [Abstract][Full Text] [Related]
34. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
Harrison SJ; Quach H; Link E; Seymour JF; Ritchie DS; Ruell S; Dean J; Januszewicz H; Johnstone R; Neeson P; Dickinson M; Nichols J; Prince HM
Blood; 2011 Dec; 118(24):6274-83. PubMed ID: 21911830
[TBL] [Abstract][Full Text] [Related]
35. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
Ryan DP; Appleman LJ; Lynch T; Supko JG; Fidias P; Clark JW; Fishman M; Zhu AX; Enzinger PC; Kashala O; Cusack J; Eder JP
Cancer; 2006 Nov; 107(10):2482-9. PubMed ID: 17036355
[TBL] [Abstract][Full Text] [Related]
36. A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
Su Y; Amiri KI; Horton LW; Yu Y; Ayers GD; Koehler E; Kelley MC; Puzanov I; Richmond A; Sosman JA
Clin Cancer Res; 2010 Jan; 16(1):348-57. PubMed ID: 20028756
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
Saltz LB; Meropol NJ; Loehrer PJ; Needle MN; Kopit J; Mayer RJ
J Clin Oncol; 2004 Apr; 22(7):1201-8. PubMed ID: 14993230
[TBL] [Abstract][Full Text] [Related]
38. Cetuximab (Erbitux)--an emerging targeted therapy for epidermal growth factor receptor-expressing tumours.
Ng M; Cunningham D
Int J Clin Pract; 2004 Oct; 58(10):970-6. PubMed ID: 15587777
[TBL] [Abstract][Full Text] [Related]
39. Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study.
Adkins D; Mehan P; Ley J; Siegel MJ; Siegel BA; Dehdashti F; Jiang X; Salama NN; Trinkaus K; Oppelt P
Lancet Oncol; 2018 Aug; 19(8):1082-1093. PubMed ID: 30001987
[TBL] [Abstract][Full Text] [Related]
40. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Pirker R; Pereira JR; Szczesna A; von Pawel J; Krzakowski M; Ramlau R; Vynnychenko I; Park K; Yu CT; Ganul V; Roh JK; Bajetta E; O'Byrne K; de Marinis F; Eberhardt W; Goddemeier T; Emig M; Gatzemeier U;
Lancet; 2009 May; 373(9674):1525-31. PubMed ID: 19410716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
